New study monitors Real-World use of LIVTENCITY for Post-Transplant CMV

NCT ID NCT06555432

Recruiting now Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 168 adults in South Korea who have had a transplant and developed a CMV infection that didn't respond to other treatments. They will take LIVTENCITY (Maribavir) as part of routine care, and researchers will track side effects and how well the drug clears the virus over about 5 months. The goal is to see if the medicine works safely in everyday practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Maribavir (LIVTENCITY tablet)
What this could lead to: If successful, this study will confirm that Maribavir is safe and effective for treating CMV after transplant in real-world settings, helping doctors manage this serious infection.
What could go wrong: This is an observational post-marketing study, not a controlled trial, so results may be less definitive. Side effects or lack of effectiveness could still occur in some patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS (CMV) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cytomegalovirus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYTOMEGALOVIRUS (CMV)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

The Catholic University of Korea, Seoul ST. Mary's Hospital
RECRUITING

Seoul, 06591, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.